Tempest Therapeutics, INC 10-Q quarterly reports

Tempest Therapeutics' Q2 2026 Form 10-Q reveals significant financial challenges, including substantial operating losses and a critical cash position, while also highlighting progress in its CAR-T therapy development.

Tempest Therapeutics and Factor Bioscience Inc. have entered into a letter agreement to modify payment obligations under their Master Services Agreement, impacting future payments and a prior deposit.

Tempest Therapeutics reports significant cash burn and a going concern warning, while advancing key oncology programs and exploring strategic alternatives.

Tempest Therapeutics reports Q2 2025 financial results, highlighting ongoing strategic review, workforce reduction, and progress in its clinical-stage oncology pipeline despite significant operating losses and going concern doubts.

Tempest Therapeutics reports Q1 2025 results, initiates strategic review, and reduces workforce amid going concern uncertainty.

Tempest Therapeutics reports its third quarter 2024 financial results and provides an update on its clinical programs, including the planned pivotal Phase 3 trial for amezalpat in liver cancer.

Tempest Therapeutics announced positive updated results from its Phase 1b/2 trial of amezalpat in liver cancer, showing a 6-month improvement in median overall survival compared to the standard of care.

Tempest Therapeutics reports a net loss of $7.9 million for the first quarter of 2024, while advancing its clinical programs and preparing for a pivotal study.